Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review

被引：3

作者：

Niraula, Saroj ^{[1
,2
]}

机构：

[1] Univ Manitoba, Sect Haematol Oncol, Dept Internal Med, Winnipeg, MB, Canada

[2] CancerCare Manitoba, Winnipeg, MB, Canada

来源：

CANCER | 2019年 / 125卷 / 18期

关键词：

cancer; drug approval; drug regulation; pan-Canadian Oncology Drug Review (pCODR); universal health; CONFLICTS-OF-INTEREST; SOCIETY; BENEFIT;

D O I：

10.1002/cncr.32209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A universal health care system has been a source of both identity and pride for Canadians for the last 6 decades. Currently, Canada actively negotiates the prices of cancer drugs but is not immune to their overwhelming financial toxicities. Prices of cancer drugs are set to ensure maximal profit based on what the market will bear rather than by the value they offer or solely because of the cost of research and development, as often is claimed by the manufacturers. The pan-Canadian Oncology Drug Review (pCODR) is mandated to provide funding recommendations to Canada's provinces and territories. For the most part, the pCODR has been crucial in assessing the cost-effectiveness and feasibility of new drugs in the Canadian context but it could assist more in safeguarding payers against extreme drug costs. Herein, the author suggests a few strategies by which national efforts such as the pCODR and its partners can help Canada to become a leader in facilitating value-based sustainable cancer care.

引用

页码：3100 / 3103

页数：4

共 50 条

[11] Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
Masucci L.
Beca J.
Sabharwal M.
Hoch J.S.
[J]. PharmacoEconomics - Open, 2017, 1 (4) : 255 - 263
[12] Trends of new cancer drug approvals from the perspective of a publicly funded healthcare system: Analyses of the pan-Canadian Oncology Drug Review (pCODR) recommendations
Niraula, Saroj
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[13] PAN-CANADIAN ONCOLOGY DRUG REVIEW RECOMMENDATIONS FOR CANCER PRODUCTS WITHOUT STATISTICALLY SIGNIFICANT OVERALL SURVIVAL DATA
Samjoo, I. A.
Patel, L.
Cameron, C.
Blazevic, C.
Grima, D.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A167 - A168
[14] Oncology drug health technology assessment recommendations: Canadian versus UK experiences
Chabot, Isabelle
Rocchi, Angela
[J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 357 - 367
[15] Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
Adam J. N. Raymakers
Kristina M. Jenei
Dean A. Regier
Michael M. Burgess
Stuart J. Peacock
[J]. PharmacoEconomics, 2021, 39 : 373 - 377
[16] Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
Raymakers, Adam J. N.
Jenei, Kristina M.
Regier, Dean A.
Burgess, Michael M.
Peacock, Stuart J.
[J]. PHARMACOECONOMICS, 2021, 39 (03) : 373 - 377
[17] The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison
Skedgel, C.
[J]. CURRENT ONCOLOGY, 2016, 23 (05) : 322 - 328
[18] Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review
Hoch, J. S.
Brown, M. B.
McMahon, C.
Nanson, J.
Rozmovits, L.
[J]. CURRENT ONCOLOGY, 2014, 21 (05) : 263 - 266
[19] Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study
Lexchin, Joel
[J]. BMJ OPEN, 2019, 9 (07):
[20] A descriptive analysis of clinician input and feedback into the CADTH pan-Canadian Oncology Drug Review process.
Trudeau, Maureen E.
Mirabi, Susan
Christiansen, Kendra
Chan, Kelvin K.
Chambers, Alexandra
Haynes, Adam E.
Mulla, Sohail
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)

← 1 2 3 4 5 →